Iradimed (IRMD) Financials

$51.09 -1.19 (-2.28%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$51.05 -0.04 (-0.08%)

As of 05/23/2025 04:04 PM Eastern

Annual Income Statements for Iradimed

This table shows Iradimed's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Income / (Loss) Attributable to Common Shareholders	19	17	13
Consolidated Net Income / (Loss)	19	17	13
Net Income / (Loss) Continuing Operations	19	17	13
Total Pre-Tax Income	24	22	16
Total Operating Income	22	20	16
Total Gross Profit	56	50	41
Total Revenue	73	66	53
Operating Revenue	73	66	53
Total Cost of Revenue	17	15	12
Operating Cost of Revenue	17	15	12
Total Operating Expenses	34	30	26
Selling, General & Admin Expense	16	15	11
Marketing Expense	16	12	13
Research & Development Expense	2.83	2.86	2.28
Total Other Income / (Expense), net	2.31	1.70	0.55
Other Income / (Expense), net	2.31	1.70	0.55
Income Tax Expense	5.04	4.55	3.35
Basic Earnings per Share	$1.52	$1.36	$1.02
Weighted Average Basic Shares Outstanding	12.67M	12.60M	12.56M
Diluted Earnings per Share	$1.50	$1.35	$1.02
Weighted Average Diluted Shares Outstanding	12.78M	12.72M	12.64M
Weighted Average Basic & Diluted Shares Outstanding	12.72M	12.66M	12.59M

This table shows Iradimed's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	5.15	5.05	4.90	4.14	4.54	5.07	4.18	3.41	3.67	3.43
Consolidated Net Income / (Loss)	5.15	5.05	4.90	4.14	4.54	5.07	4.18	3.41	3.67	3.43
Net Income / (Loss) Continuing Operations	5.15	5.05	4.90	4.14	4.54	5.07	4.18	3.41	3.67	3.43
Total Pre-Tax Income	6.34	6.42	6.27	5.24	5.68	6.41	5.30	4.35	4.70	4.24
Total Operating Income	5.80	5.79	5.63	4.75	5.16	5.91	4.96	4.01	4.25	4.13
Total Gross Profit	15	14	14	13	13	13	12	12	11	11
Total Revenue	19	18	18	18	17	17	16	15	15	13
Operating Revenue	19	18	18	18	17	17	16	15	15	13
Total Cost of Revenue	4.63	4.13	3.92	4.21	4.04	3.67	3.94	3.75	3.64	2.86
Operating Cost of Revenue	4.63	4.13	3.92	4.21	4.04	3.67	3.94	3.75	3.64	2.86
Total Operating Expenses	8.96	8.40	8.38	8.64	8.25	6.93	7.22	7.71	6.97	6.41
Selling, General & Admin Expense	3.87	3.97	4.10	3.99	4.27	3.62	3.31	3.92	2.70	2.88
Marketing Expense	7.52	3.80	3.48	0.82	5.54	2.86	2.95	0.79	3.67	3.04
Research & Development Expense	-2.44	0.64	0.80	3.83	-1.56	0.45	0.96	3.00	0.60	0.49
Total Other Income / (Expense), net	0.54	0.63	0.64	0.50	0.52	0.50	0.34	0.34	0.45	0.11
Other Income / (Expense), net	0.54	0.63	0.64	0.50	0.52	0.50	0.34	0.34	0.45	0.11
Income Tax Expense	1.20	1.37	1.37	1.11	1.14	1.34	1.12	0.94	1.03	0.81
Basic Earnings per Share	$0.40	$0.40	$0.39	$0.33	$0.36	$0.40	$0.33	$0.27	$0.29	$0.27
Weighted Average Basic Shares Outstanding	12.67M	12.67M	12.66M	12.66M	12.60M	12.60M	12.60M	12.59M	12.56M	12.56M
Diluted Earnings per Share	$0.40	$0.40	$0.38	$0.32	$0.35	$0.40	$0.33	$0.27	$0.29	$0.27
Weighted Average Diluted Shares Outstanding	12.78M	12.78M	12.76M	12.75M	12.72M	12.74M	12.72M	12.69M	12.64M	12.63M
Weighted Average Basic & Diluted Shares Outstanding	12.72M	12.67M	12.67M	12.66M	12.66M	12.61M	12.60M	12.59M	12.59M	12.57M

This table details how cash moves in and out of Iradimed's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Change in Cash & Equivalents	2.47	-8.20	-4.04
Net Cash From Operating Activities	26	13	10
Net Cash From Continuing Operating Activities	26	13	10
Net Income / (Loss) Continuing Operations	19	17	13
Consolidated Net Income / (Loss)	19	17	13
Depreciation Expense	0.82	0.77	0.67
Non-Cash Adjustments To Reconcile Net Income	2.52	2.61	1.59
Changes in Operating Assets and Liabilities, net	3.05	-7.11	-5.02
Net Cash From Investing Activities	-8.82	-8.01	-1.37
Net Cash From Continuing Investing Activities	-8.82	-8.01	-1.37
Purchase of Property, Plant & Equipment	-8.82	-8.01	-1.87
Net Cash From Financing Activities	-14	-14	-13
Net Cash From Continuing Financing Activities	-14	-14	-13
Payment of Dividends	-14	-13	-13
Other Financing Activities, net	-0.66	-0.43	-0.15
Cash Income Taxes Paid	6.51	5.35	1.71

This table details how cash moves in and out of Iradimed's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	0.51	3.19	3.41	-4.64	3.02	0.92	3.05	-15	2.37	3.43
Net Cash From Operating Activities	5.99	9.12	6.64	3.88	3.91	1.39	3.51	4.65	3.04	3.94
Net Cash From Continuing Operating Activities	6.08	9.03	6.64	3.88	3.91	1.39	3.51	4.65	3.06	3.94
Net Income / (Loss) Continuing Operations	5.15	5.05	4.90	4.14	4.54	5.07	4.18	3.41	3.67	3.43
Consolidated Net Income / (Loss)	5.15	5.05	4.90	4.14	4.54	5.07	4.18	3.41	3.67	3.43
Depreciation Expense	0.19	0.20	0.20	0.23	0.21	0.19	0.19	0.18	-0.69	0.44
Non-Cash Adjustments To Reconcile Net Income	1.13	0.02	0.74	0.63	0.59	0.57	0.65	0.81	0.56	0.43
Changes in Operating Assets and Liabilities, net	-0.40	3.75	0.80	-1.11	-1.42	-4.43	-1.50	0.25	-0.48	-0.36
Net Cash From Investing Activities	-3.06	-4.01	-1.27	-0.48	-0.63	-0.44	-0.38	-6.56	-0.47	-0.56
Net Cash From Continuing Investing Activities	-3.06	-4.01	-1.27	-0.48	-0.63	-0.44	-0.38	-6.56	-0.47	-0.56
Purchase of Property, Plant & Equipment	-3.06	-4.01	-1.27	-0.48	-0.63	-0.44	-0.38	-6.56	-0.47	-0.56
Net Cash From Financing Activities	-2.42	-1.92	-1.96	-8.04	-0.26	-0.03	-0.09	-13	-0.20	0.05
Net Cash From Continuing Financing Activities	-2.42	-1.92	-1.96	-8.04	-0.26	-0.03	-0.09	-13	-0.20	0.05
Payment of Dividends	-1.90	-1.90	-1.90	-7.98	-	-	-	-13	-	-
Other Financing Activities, net	-0.52	-0.02	-0.06	-0.06	-0.26	-0.03	-0.09	-0.05	-0.20	0.05
Cash Income Taxes Paid	2.06	1.45	2.82	0.19	1.22	1.38	2.76	0.00	0.95	-

This table presents Iradimed's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Total Assets	98	92	86
Total Current Assets	75	76	77
Cash & Equivalents	52	50	58
Accounts Receivable	11	12	13
Inventories, net	10	13	5.37
Prepaid Expenses	2.05	1.19	0.63
Plant, Property, & Equipment, net	17	9.29	2.40
Total Noncurrent Assets	6.27	6.87	5.62
Intangible Assets	3.10	2.52	2.07
Noncurrent Deferred & Refundable Income Taxes	2.82	2.12	0.70
Other Noncurrent Operating Assets	0.35	2.22	2.85
Total Liabilities & Shareholders' Equity	98	92	86
Total Liabilities	12	21	12
Total Current Liabilities	8.51	16	8.55
Accounts Payable	1.90	1.86	1.80
Accrued Expenses	0.12	0.12	0.09
Dividends Payable	0.00	7.98	0.00
Current Deferred Revenue	2.26	2.57	3.37
Current Deferred & Payable Income Tax Liabilities	0.00	0.25	0.00
Current Employee Benefit Liabilities	3.77	2.78	2.87
Other Taxes Payable	0.16	0.10	0.12
Other Current Liabilities	0.30	0.68	0.29
Total Noncurrent Liabilities	2.99	4.41	3.29
Noncurrent Deferred Revenue	2.99	2.79	1.38
Other Noncurrent Operating Liabilities	0.00	1.62	1.91
Total Equity & Noncontrolling Interests	87	71	74
Total Preferred & Common Equity	87	71	74
Total Common Equity	87	71	74
Common Stock	30	28	26
Retained Earnings	57	43	47

This table presents Iradimed's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	94	90	88	87	81	76	80
Total Current Assets	74	74	72	72	66	61	72
Cash & Equivalents	52	49	45	47	46	43	56
Accounts Receivable	10	12	13	13	11	12	11
Inventories, net	11	12	13	12	8.42	6.31	5.24
Prepaid Expenses	0.95	1.02	1.04	0.74	0.77	0.68	0.39
Plant, Property, & Equipment, net	14	10	9.45	8.89	8.72	8.64	2.29
Total Noncurrent Assets	5.80	5.90	6.68	6.59	6.62	5.68	5.38
Intangible Assets	2.89	2.75	2.67	2.46	2.35	2.21	1.88
Noncurrent Deferred & Refundable Income Taxes	2.46	2.59	1.88	1.80	1.77	0.62	0.99
Other Noncurrent Operating Assets	0.45	0.56	2.12	2.32	2.50	2.85	2.51
Total Liabilities & Shareholders' Equity	94	90	88	87	81	76	80
Total Liabilities	11	10	12	13	12	11	9.77
Total Current Liabilities	8.06	7.46	7.62	7.88	7.59	6.76	5.60
Accounts Payable	1.40	1.12	1.29	2.78	2.55	1.76	0.96
Accrued Expenses	0.12	0.12	0.12	0.11	0.11	0.10	0.10
Dividends Payable	0.00	0.00	0.00	-	-	-	-
Current Deferred Revenue	2.56	2.54	2.34	1.92	1.71	2.07	1.59
Current Deferred & Payable Income Tax Liabilities	0.00	0.00	0.93	-	-	0.49	-
Current Employee Benefit Liabilities	3.28	2.90	2.14	2.29	2.33	1.62	2.35
Other Taxes Payable	0.19	0.16	0.14	0.10	0.22	0.06	0.18
Other Current Liabilities	0.51	0.62	0.67	0.67	0.66	0.66	0.43
Total Noncurrent Liabilities	2.75	2.82	4.28	4.96	4.85	4.52	4.17
Noncurrent Deferred Revenue	2.75	2.82	2.76	3.23	3.01	2.59	2.18
Other Noncurrent Operating Liabilities	0.00	0.00	1.52	1.72	1.83	1.94	1.99
Total Equity & Noncontrolling Interests	83	80	76	75	69	64	70
Total Preferred & Common Equity	83	80	76	75	69	64	70
Total Common Equity	83	80	76	75	69	64	70
Common Stock	30	29	29	28	27	27	26
Retained Earnings	54	50	47	47	42	37	44

This table displays calculated financial ratios and metrics derived from Iradimed's official financial filings.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Growth Metrics	-	-	-
Revenue Growth	11.71%	23.00%	27.48%
EBITDA Growth	11.51%	33.54%	49.88%
EBIT Growth	11.67%	34.35%	64.50%
NOPAT Growth	9.83%	27.89%	33.11%
Net Income Growth	11.87%	34.02%	37.56%
EPS Growth	11.11%	32.35%	37.84%
Operating Cash Flow Growth	90.30%	34.08%	-10.80%
Free Cash Flow Firm Growth	547.14%	-69.70%	-29.77%
Invested Capital Growth	16.71%	88.61%	62.44%
Revenue Q/Q Growth	2.72%	4.11%	5.94%
EBITDA Q/Q Growth	2.67%	9.10%	3.12%
EBIT Q/Q Growth	2.81%	4.71%	10.90%
NOPAT Q/Q Growth	3.46%	5.33%	-4.34%
Net Income Q/Q Growth	3.26%	5.30%	-1.68%
EPS Q/Q Growth	3.45%	4.65%	-1.92%
Operating Cash Flow Q/Q Growth	8.81%	6.94%	-3.16%
Free Cash Flow Firm Q/Q Growth	-3.72%	37.40%	-13.57%
Invested Capital Q/Q Growth	9.06%	6.51%	10.81%
Profitability Metrics	-	-	-
Gross Margin	76.94%	76.50%	77.45%
EBITDA Margin	34.26%	34.32%	31.61%
Operating Margin	29.99%	30.56%	29.32%
EBIT Margin	33.14%	33.16%	30.36%
Profit (Net Income) Margin	26.26%	26.22%	24.07%
Tax Burden Percent	79.23%	79.09%	79.28%
Interest Burden Percent	100.00%	100.00%	100.00%
Effective Tax Rate	20.77%	20.91%	20.72%
Return on Invested Capital (ROIC)	54.20%	69.89%	97.62%
ROIC Less NNEP Spread (ROIC-NNEP)	50.31%	67.19%	96.89%
Return on Net Nonoperating Assets (RNNOA)	-29.89%	-46.19%	-80.03%
Return on Equity (ROE)	24.31%	23.70%	17.59%
Cash Return on Invested Capital (CROIC)	38.78%	8.49%	50.03%
Operating Return on Assets (OROA)	25.49%	24.47%	19.22%
Return on Assets (ROA)	20.20%	19.35%	15.24%
Return on Common Equity (ROCE)	24.31%	23.70%	17.59%
Return on Equity Simple (ROE_SIMPLE)	22.15%	24.07%	17.41%
Net Operating Profit after Tax (NOPAT)	17	16	12
NOPAT Margin	23.76%	24.17%	23.24%
Net Nonoperating Expense Percent (NNEP)	3.89%	2.70%	0.73%
Return On Investment Capital (ROIC_SIMPLE)	20.05%	22.19%	-
Cost of Revenue to Revenue	23.06%	23.50%	22.55%
SG&A Expenses to Revenue	21.76%	23.07%	20.07%
R&D to Revenue	3.87%	4.36%	4.27%
Operating Expenses to Revenue	46.95%	45.95%	48.13%
Earnings before Interest and Taxes (EBIT)	24	22	16
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	25	23	17
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	8.00	8.27	4.59
Price to Tangible Book Value (P/TBV)	8.30	8.58	4.72
Price to Revenue (P/Rev)	9.49	9.01	6.34
Price to Earnings (P/E)	36.13	34.37	26.33
Dividend Yield	1.70%	3.26%	3.72%
Earnings Yield	2.77%	2.91%	3.80%
Enterprise Value to Invested Capital (EV/IC)	18.58	18.26	17.81
Enterprise Value to Revenue (EV/Rev)	8.78	8.25	5.25
Enterprise Value to EBITDA (EV/EBITDA)	25.61	24.04	16.61
Enterprise Value to EBIT (EV/EBIT)	26.48	24.89	17.30
Enterprise Value to NOPAT (EV/NOPAT)	36.93	34.15	22.59
Enterprise Value to Operating Cash Flow (EV/OCF)	25.08	40.18	27.87
Enterprise Value to Free Cash Flow (EV/FCFF)	51.61	281.19	44.07
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00
Financial Leverage	-0.59	-0.69	-0.83
Leverage Ratio	1.20	1.22	1.15
Compound Leverage Factor	1.20	1.22	1.15
Debt to Total Capital	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00
Altman Z-Score	39.42	20.02	20.11
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	8.84	4.65	9.06
Quick Ratio	7.38	3.80	8.33
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	12	1.92	6.35
Operating Cash Flow to CapEx	290.63%	168.16%	535.61%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00
Efficiency Ratios	-	-	-
Asset Turnover	0.77	0.74	0.63
Accounts Receivable Turnover	6.43	5.14	5.79
Inventory Turnover	1.45	1.69	2.49
Fixed Asset Turnover	5.61	11.22	23.85
Accounts Payable Turnover	9.00	8.43	9.31
Days Sales Outstanding (DSO)	56.76	70.98	63.04
Days Inventory Outstanding (DIO)	250.90	215.51	146.80
Days Payable Outstanding (DPO)	40.55	43.32	39.20
Cash Conversion Cycle (CCC)	267.11	243.17	170.63
Capital & Investment Metrics	-	-	-
Invested Capital	35	30	16
Invested Capital Turnover	2.28	2.89	4.20
Increase / (Decrease) in Invested Capital	4.95	14	6.04
Enterprise Value (EV)	643	541	280
Market Capitalization	695	591	338
Book Value per Share	$6.85	$5.67	$5.86
Tangible Book Value per Share	$6.61	$5.47	$5.70
Total Capital	87	71	74
Total Debt	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00
Net Debt	-52	-50	-58
Capital Expenditures (CapEx)	8.82	8.01	1.87
Debt-free, Cash-free Net Working Capital (DFCFNWC)	14	9.91	11
Debt-free Net Working Capital (DFNWC)	67	60	69
Net Working Capital (NWC)	67	60	69
Net Nonoperating Expense (NNE)	-1.83	-1.35	-0.44
Net Nonoperating Obligations (NNO)	-52	-42	-58
Total Depreciation and Amortization (D&A)	0.82	0.77	0.67
Debt-free, Cash-free Net Working Capital to Revenue	19.79%	15.12%	20.59%
Debt-free Net Working Capital to Revenue	91.11%	91.02%	129.33%
Net Working Capital to Revenue	91.11%	91.02%	129.33%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	$1.52	$1.36	$1.02
Adjusted Weighted Average Basic Shares Outstanding	12.67M	12.60M	12.56M
Adjusted Diluted Earnings per Share	$1.50	$1.35	$1.02
Adjusted Weighted Average Diluted Shares Outstanding	12.78M	12.72M	12.64M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	12.72M	12.66M	12.59M
Normalized Net Operating Profit after Tax (NOPAT)	17	16	12
Normalized NOPAT Margin	23.76%	24.17%	23.24%
Pre Tax Income Margin	33.14%	33.16%	30.36%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	71.11%	76.91%	97.90%
Augmented Payout Ratio	71.11%	76.91%	97.90%

This table displays calculated financial ratios and metrics derived from Iradimed's official financial filings.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	11.10%	11.04%	11.15%	13.72%	17.42%	23.10%	26.80%	25.70%	25.19%	22.92%
EBITDA Growth	11.08%	0.26%	17.91%	20.68%	46.78%	41.20%	17.37%	29.72%	14.59%	36.07%
EBIT Growth	11.66%	0.15%	18.32%	20.55%	20.79%	51.23%	26.77%	42.15%	51.07%	36.96%
NOPAT Growth	14.13%	-2.46%	12.36%	19.38%	24.09%	39.71%	21.18%	25.58%	-14.54%	30.02%
Net Income Growth	13.37%	-0.35%	17.26%	21.45%	23.58%	47.86%	28.97%	36.97%	-5.63%	33.03%
EPS Growth	14.29%	0.00%	15.15%	18.52%	20.69%	48.15%	26.92%	35.00%	-6.45%	35.00%
Operating Cash Flow Growth	53.02%	554.54%	88.93%	-16.42%	28.75%	-64.64%	114.36%	225.77%	-9.72%	16.58%
Free Cash Flow Firm Growth	97.49%	107.42%	35.47%	16.66%	-260.61%	-296.70%	-221.50%	-637.03%	-175.03%	-144.41%
Invested Capital Growth	16.71%	13.98%	34.35%	43.74%	88.61%	96.22%	68.66%	85.86%	62.44%	65.36%
Revenue Q/Q Growth	5.80%	2.21%	1.88%	0.84%	5.74%	2.32%	4.23%	4.11%	10.86%	5.39%
EBITDA Q/Q Growth	-1.16%	2.28%	18.26%	-7.09%	-10.78%	20.28%	21.04%	13.00%	-14.17%	-0.02%
EBIT Q/Q Growth	-1.15%	2.38%	19.56%	-7.71%	-11.34%	20.95%	21.81%	-7.52%	11.00%	1.38%
NOPAT Q/Q Growth	3.31%	3.53%	17.44%	-9.14%	-11.71%	19.26%	24.77%	-5.55%	-0.59%	3.44%
Net Income Q/Q Growth	1.93%	3.03%	18.49%	-8.88%	-10.41%	21.23%	22.72%	-7.28%	7.19%	5.74%
EPS Q/Q Growth	0.00%	5.26%	18.75%	-8.57%	-12.50%	21.21%	22.22%	-6.90%	7.41%	3.85%
Operating Cash Flow Q/Q Growth	-34.32%	37.32%	70.96%	-0.75%	180.93%	-60.36%	-24.37%	52.89%	-22.84%	140.26%
Free Cash Flow Firm Q/Q Growth	-136.88%	118.69%	37.36%	41.97%	-9.19%	-62.60%	19.11%	-151.09%	-20.11%	-31.78%
Invested Capital Q/Q Growth	9.06%	1.85%	0.46%	4.59%	6.51%	20.05%	7.48%	37.24%	10.81%	3.19%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	76.13%	77.44%	78.14%	76.07%	76.86%	77.78%	75.55%	75.74%	75.49%	78.63%
EBITDA Margin	33.73%	36.10%	36.08%	31.08%	33.73%	39.98%	34.01%	29.29%	26.98%	34.85%
Operating Margin	29.91%	31.59%	31.39%	26.98%	29.57%	35.78%	30.77%	25.89%	28.62%	30.82%
EBIT Margin	32.72%	35.02%	34.97%	29.80%	32.56%	38.83%	32.85%	28.11%	31.65%	31.61%
Profit (Net Income) Margin	26.54%	27.55%	27.34%	23.51%	26.01%	30.70%	25.91%	22.01%	24.72%	25.56%
Tax Burden Percent	81.12%	78.67%	78.18%	78.89%	79.90%	79.07%	78.89%	78.31%	78.10%	80.88%
Interest Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Effective Tax Rate	18.88%	21.33%	21.82%	21.11%	20.10%	20.93%	21.11%	21.69%	21.90%	19.12%
Return on Invested Capital (ROIC)	55.36%	59.53%	62.78%	54.83%	68.31%	84.83%	78.74%	69.05%	93.87%	110.24%
ROIC Less NNEP Spread (ROIC-NNEP)	54.42%	58.53%	61.72%	53.94%	67.47%	84.06%	78.20%	68.48%	93.29%	110.09%
Return on Net Nonoperating Assets (RNNOA)	-32.33%	-36.47%	-39.17%	-33.75%	-46.39%	-59.60%	-56.80%	-50.58%	-77.05%	-91.89%
Return on Equity (ROE)	23.02%	23.06%	23.61%	21.07%	21.92%	25.24%	21.94%	18.47%	16.82%	18.34%
Cash Return on Invested Capital (CROIC)	38.78%	43.45%	33.05%	26.72%	8.49%	6.67%	23.18%	18.52%	50.03%	64.58%
Operating Return on Assets (OROA)	25.16%	27.50%	28.35%	24.65%	24.03%	29.29%	25.03%	21.45%	20.03%	20.14%
Return on Assets (ROA)	20.41%	21.63%	22.17%	19.45%	19.20%	23.16%	19.75%	16.79%	15.65%	16.29%
Return on Common Equity (ROCE)	23.02%	23.06%	23.61%	21.07%	21.92%	25.24%	21.94%	18.47%	16.82%	18.34%
Return on Equity Simple (ROE_SIMPLE)	0.00%	22.33%	23.40%	23.55%	0.00%	21.90%	21.29%	21.37%	0.00%	18.70%
Net Operating Profit after Tax (NOPAT)	4.71	4.55	4.40	3.75	4.12	4.67	3.92	3.14	3.32	3.34
NOPAT Margin	24.27%	24.85%	24.54%	21.29%	23.62%	28.29%	24.27%	20.28%	22.35%	24.93%
Net Nonoperating Expense Percent (NNEP)	0.94%	1.01%	1.06%	0.89%	0.84%	0.78%	0.54%	0.57%	0.58%	0.15%
Return On Investment Capital (ROIC_SIMPLE)	5.42%	-	-	-	5.77%	-	-	-	-	-
Cost of Revenue to Revenue	23.87%	22.56%	21.86%	23.93%	23.14%	22.22%	24.45%	24.26%	24.51%	21.37%
SG&A Expenses to Revenue	19.98%	21.65%	22.90%	22.68%	24.49%	21.90%	20.54%	25.33%	18.14%	21.49%
R&D to Revenue	-12.56%	3.49%	4.47%	21.75%	-8.91%	2.74%	5.96%	19.39%	4.07%	3.67%
Operating Expenses to Revenue	46.21%	45.85%	46.75%	49.09%	47.29%	42.00%	44.78%	49.85%	46.87%	47.81%
Earnings before Interest and Taxes (EBIT)	6.34	6.42	6.27	5.24	5.68	6.41	5.30	4.35	4.70	4.24
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	6.54	6.62	6.47	5.47	5.89	6.60	5.49	4.53	4.01	4.67
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	8.00	7.64	6.96	7.27	8.27	7.34	8.53	7.54	4.59	5.14
Price to Tangible Book Value (P/TBV)	8.30	7.91	7.21	7.53	8.58	7.60	8.84	7.81	4.72	5.29
Price to Revenue (P/Rev)	9.49	8.94	7.98	8.17	9.01	8.70	9.84	8.60	6.34	7.13
Price to Earnings (P/E)	36.13	34.21	29.75	30.87	34.37	33.54	40.10	35.30	26.33	27.51
Dividend Yield	1.70%	1.55%	1.44%	3.50%	3.26%	2.42%	2.25%	2.72%	3.72%	3.50%
Earnings Yield	2.77%	2.92%	3.36%	3.24%	2.91%	2.98%	2.49%	2.83%	3.80%	3.64%
Enterprise Value to Invested Capital (EV/IC)	18.58	18.46	16.25	16.39	18.26	18.00	23.43	20.52	17.81	21.39
Enterprise Value to Revenue (EV/Rev)	8.78	8.21	7.28	7.51	8.25	7.95	9.07	7.84	5.25	6.03
Enterprise Value to EBITDA (EV/EBITDA)	25.61	23.95	20.72	21.68	24.04	24.28	29.04	24.74	16.61	18.56
Enterprise Value to EBIT (EV/EBIT)	26.48	24.79	21.44	22.45	24.89	24.13	29.21	25.33	17.30	20.79
Enterprise Value to NOPAT (EV/NOPAT)	36.93	34.80	29.88	30.88	34.15	33.30	39.60	33.96	22.59	23.42
Enterprise Value to Operating Cash Flow (EV/OCF)	25.08	24.86	31.97	40.00	40.18	39.78	35.88	33.37	27.87	29.25
Enterprise Value to Free Cash Flow (EV/FCFF)	51.61	45.27	56.38	72.36	281.19	357.68	126.94	144.13	44.07	41.28
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.59	-0.62	-0.63	-0.63	-0.69	-0.71	-0.73	-0.74	-0.83	-0.83
Leverage Ratio	1.20	1.15	1.15	1.17	1.22	1.16	1.17	1.17	1.15	1.15
Compound Leverage Factor	1.20	1.15	1.15	1.17	1.22	1.16	1.17	1.17	1.15	1.15
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	38.82	37.97	35.04	30.51	19.45	28.19	30.95	28.31	19.66	24.61
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	8.84	9.21	9.87	9.44	4.65	9.13	8.71	9.07	9.06	12.83
Quick Ratio	7.38	7.70	8.11	7.64	3.80	7.55	7.50	8.04	8.33	11.82
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-0.25	0.67	-3.56	-5.69	-9.80	-8.97	-5.52	-6.82	-2.72	-2.26
Operating Cash Flow to CapEx	195.87%	227.24%	522.81%	811.01%	618.27%	317.22%	928.79%	70.86%	644.27%	708.12%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.77	0.79	0.81	0.83	0.74	0.75	0.76	0.76	0.63	0.64
Accounts Receivable Turnover	6.43	6.16	6.03	5.51	5.14	5.37	6.15	6.26	5.79	6.75
Inventory Turnover	1.45	1.42	1.55	1.67	1.69	1.77	2.14	2.41	2.49	2.27
Fixed Asset Turnover	5.61	6.19	7.24	7.48	11.22	11.27	10.93	10.46	23.85	22.85
Accounts Payable Turnover	9.00	7.79	8.62	10.43	8.43	8.01	8.42	8.88	9.31	12.18
Days Sales Outstanding (DSO)	56.76	59.25	60.50	66.22	70.98	67.91	59.33	58.32	63.04	54.07
Days Inventory Outstanding (DIO)	250.90	256.56	236.09	218.72	215.51	205.64	170.51	151.44	146.80	160.54
Days Payable Outstanding (DPO)	40.55	46.83	42.33	35.00	43.32	45.57	43.35	41.11	39.20	29.98
Cash Conversion Cycle (CCC)	267.11	268.98	254.26	249.94	243.17	227.99	186.49	168.66	170.63	184.62
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	35	32	31	31	30	28	23	22	16	14
Invested Capital Turnover	2.28	2.40	2.56	2.58	2.89	3.00	3.24	3.41	4.20	4.42
Increase / (Decrease) in Invested Capital	4.95	3.89	7.96	9.43	14	14	9.43	9.96	6.04	5.60
Enterprise Value (EV)	643	585	506	508	541	501	543	443	280	303
Market Capitalization	695	637	555	553	591	548	589	485	338	359
Book Value per Share	$6.85	$6.59	$6.29	$6.01	$5.67	$5.92	$5.48	$5.11	$5.86	$5.55
Tangible Book Value per Share	$6.61	$6.36	$6.07	$5.80	$5.47	$5.72	$5.29	$4.93	$5.70	$5.40
Total Capital	87	83	80	76	71	75	69	64	74	70
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-52	-52	-49	-45	-50	-47	-46	-43	-58	-56
Capital Expenditures (CapEx)	3.06	4.01	1.27	0.48	0.63	0.44	0.38	6.56	0.47	0.56
Debt-free, Cash-free Net Working Capital (DFCFNWC)	14	15	18	19	9.91	17	13	12	11	11
Debt-free Net Working Capital (DFNWC)	67	66	66	64	60	64	59	55	69	66
Net Working Capital (NWC)	67	66	66	64	60	64	59	55	69	66
Net Nonoperating Expense (NNE)	-0.44	-0.50	-0.50	-0.39	-0.42	-0.40	-0.26	-0.27	-0.35	-0.09
Net Nonoperating Obligations (NNO)	-52	-52	-49	-45	-42	-47	-46	-43	-58	-56
Total Depreciation and Amortization (D&A)	0.19	0.20	0.20	0.23	0.21	0.19	0.19	0.18	-0.69	0.44
Debt-free, Cash-free Net Working Capital to Revenue	19.79%	20.34%	25.31%	28.28%	15.12%	27.48%	21.18%	20.84%	20.59%	21.22%
Debt-free Net Working Capital to Revenue	91.11%	92.87%	95.16%	94.95%	91.02%	101.71%	97.71%	96.59%	129.33%	131.72%
Net Working Capital to Revenue	91.11%	92.87%	95.16%	94.95%	91.02%	101.71%	97.71%	96.59%	129.33%	131.72%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.40	$0.40	$0.39	$0.33	$0.36	$0.40	$0.33	$0.27	$0.29	$0.27
Adjusted Weighted Average Basic Shares Outstanding	12.67M	12.67M	12.66M	12.66M	12.60M	12.60M	12.60M	12.59M	12.56M	12.56M
Adjusted Diluted Earnings per Share	$0.40	$0.40	$0.38	$0.32	$0.35	$0.40	$0.33	$0.27	$0.29	$0.27
Adjusted Weighted Average Diluted Shares Outstanding	12.78M	12.78M	12.76M	12.75M	12.72M	12.74M	12.72M	12.69M	12.64M	12.63M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	12.72M	12.67M	12.67M	12.66M	12.66M	12.61M	12.60M	12.59M	12.59M	12.57M
Normalized Net Operating Profit after Tax (NOPAT)	4.71	4.55	4.40	3.75	4.12	4.67	3.92	3.14	3.32	3.34
Normalized NOPAT Margin	24.27%	24.85%	24.54%	21.29%	23.62%	28.29%	24.27%	20.28%	22.35%	24.93%
Pre Tax Income Margin	32.72%	35.02%	34.97%	29.80%	32.56%	38.83%	32.85%	28.11%	31.65%	31.61%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	71.11%	63.22%	52.97%	44.50%	76.91%	80.99%	90.03%	96.18%	97.90%	96.26%
Augmented Payout Ratio	71.11%	63.22%	52.97%	44.50%	76.91%	80.99%	90.03%	96.18%	97.90%	96.26%

Frequently Asked Questions About Iradimed's Financials

When does Iradimed's fiscal year end?

According to the most recent income statement we have on file, Iradimed's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Iradimed's net income changed over the last 2 years?

Iradimed's net income appears to be on an upward trend, with a most recent value of $19.23 million in 2024, rising from $12.83 million in 2022. The previous period was $17.19 million in 2023. See Iradimed's forecast for analyst expectations on what’s next for the company.

What is Iradimed's operating income?

Iradimed's total operating income in 2024 was $21.96 million, based on the following breakdown:

Total Gross Profit: $56.35 million
Total Operating Expenses: $34.39 million

How has Iradimed revenue changed over the last 2 years?

Over the last 2 years, Iradimed's total revenue changed from $53.30 million in 2022 to $73.24 million in 2024, a change of 37.4%.

How much debt does Iradimed have?

Iradimed's total liabilities were at $11.51 million at the end of 2024, a 44.5% decrease from 2023, and a 2.8% decrease since 2022.

How much cash does Iradimed have?

In the past 2 years, Iradimed's cash and equivalents has ranged from $49.76 million in 2023 to $57.96 million in 2022, and is currently $52.23 million as of their latest financial filing in 2024.

How has Iradimed's book value per share changed over the last 2 years?

Over the last 2 years, Iradimed's book value per share changed from 5.86 in 2022 to 6.85 in 2024, a change of 16.8%.

Related Companies

This page (NASDAQ:IRMD) was last updated on 5/24/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Iradimed (IRMD) Financials

Frequently Asked Questions About Iradimed's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Iradimed (IRMD) Financials

Annual Income Statements for Iradimed

Quarterly Income Statements for Iradimed

Annual Cash Flow Statements for Iradimed

Quarterly Cash Flow Statements for Iradimed

Annual Balance Sheets for Iradimed

Quarterly Balance Sheets for Iradimed

Annual Metrics And Ratios for Iradimed

Quarterly Metrics And Ratios for Iradimed

Frequently Asked Questions About Iradimed's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools